← All trials
NCT04669678
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 17, 2021
- Primary completion
- Dec 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- Dec 17, 2020
- Last posted
- Apr 20, 2023
- Enrollment
- 105
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Alabama, BirminghamLead sponsor
- University of WashingtonLead sponsor
- MerckCollaborator
- University of WashingtonReponsible party - principal investigator
- Wits UniversityCollaborator
- University of WashingtonOfficial
- University of Alabama, BirminghamSponsor investigator
- University of WashingtonCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.